NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts ...
Galectin Therapeutics Inc. NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today ...
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three ...
Certain strains of a bacterium found in the gut of some animals, Lactobacillus plantarum, are able to counter hyperuricemia, a condition caused by high levels of uric acid in the blood.
In the May 6 Nature the investigators delved into the dynamics of LTA-α in atherosclerotic lesions, identifying a binding partner for LTA-α, the lectin galectin-2. In an evaluation of more than ...